Company / Operating Margin
Aclaris Therapeutics, Inc. Operating Margin History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-975.9%
FY2025
5-year range
-1327.1% / -302.0%
FY2021-FY2025
Trend
-213.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin changed -213% YoY in FY2025, a notable deviation from the 8-year average annual change of -61%.
Based on SEC 10-K filings.
-975.9% in FY2025 with a 5-year CAGR of +402.4%.
Improved from -1327.1% to -975.9% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- -673.9pp
- 5-Year Change
- +402.4pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, operating margin decreased 213.2% year-over-year.
- Peak operating margin was recorded in FY2022.
- Lowest operating margin in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -975.9% | -213.2% |
| FY2024 | -311.6% | +76.5% |
| FY2023 | -1327.1% | -339.4% |
| FY2022 | -302.0% | +77.2% |
| FY2021 | -1327.1% | +3.7% |
| FY2020 | -1378.3% | +57.3% |
| FY2019 | -3230.0% | -134.3% |
| FY2018 | -1378.3% | -12.2% |
| FY2017 | -1228.0% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026